No Detail Found!

Method Development and Validation of RP-HPLC Method for Estimation of Eplerenone in Bulk and Pharmaceutical Formulations.

Author(s)
Saima Asif Faculty of Pharmacy, Jinnah University for Women, Karachi, Pakistan
Safila Naveed Faculty of Pharmacy, Jinnah University for Women, Karachi, Pakistan
Khan Usmanghani Faculty of Pharmacy, Jinnah University for Women, Karachi, Pakistan; Herbion Pakistan (Pvt.) Limited, Karachi, Pakistan
M Tanweer Alam Drug Regulatory Authority of Pakistan, Faculty of Pharmacy, Jinnah University for Women, Karachi, Pakistan
Ghulam Sarwer Faculty of Pharmacy, Jinnah University for Women, Karachi, Pakistan
Abstract
Objective: This method focused on development of simple, selective and precise liquid chromatographic method for determination of Eplerenone in API (Active Pharmaceutical Ingredient) and pharmaceutical formulations. Methods: This chromatographic method employed a C18 column with Isocratic mobile phase consisting of Acetonitrile and Phosphoric acid 0.1% (50:50, v/v). The UV detection was performed at 241 nm. This was followed with validation of developed procedure for as per ICH guidelines. Results: The validation parameters of linearity, accuracy, precision, and specificity were found to be distinct able. There was no interference detected with neither excipients nor degradation products in the determination of active pharmaceutical ingredient and tablet formulation. The results presented a linear response over a range from 2 to 20 µg/ml with good accuracy and intraand inter-day precision. The recovered values from pharmaceutical dosage form ranged from 98 to 102%. Moreover, stability of the procedure was evaluated by subjecting solutions of Eplerenone and its drug products to four different stress conditions: acidic, oxidative, reductive and ultraviolet degradation. Moreover, forced degradation study was also performed under thermal stress and photolytic conditions. Conclusions: Overall, the method developed was found to be suitable for routine quantitative determination of the active in both bulk and pharmaceutical tablet dosage form.
Publication Details
Page(s) 20-26
DOI DOI not available
Published Journal: RADS Journal of Pharmacy & Pharmaceutical Sciences, Volume: 5, Issue: 2, Year: 2017

Request the full text from PASTIC

Keywords
Pharmaceutical formulations, active pharmaceutical ingredient
References
ShailajaB,SwarnaK,AfreenM, 2015.Kumar A. A rapid assay method development and validation for the estimation of Eplerenone in tablets by UV spectrophotometry,Int J Pharm Pharm Sci 7 327 -30
WeinbergerMH,RonikerB,KrauseSL,WeissRJ, 2002.Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension,Am J Hypertens 15 709 -16
BurgessED,LacourciéreY,Ruilope-UriosteLM,OparilS,KleimanJH,KrauseS,RonikerB,MaurathC, 2003.Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension,Clin Pharmacol Ther 25 2388 -404
RogersJK,McMurrayJJ,PocockSJ,ZannadF,KrumH,van VeldhuisenDJ,SwedbergK,ShiH,VincentJ,PittB., 2012.Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations,Circulation -
WhiteWB,DuprezD,St HillaireR,KrauseS,RonikerB,Kuse-HamiltonJ,WeberMA, 2003.Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension,Hypertension 41 1021 -6
StierCT, 2003.Eplerenone: a selective aldosterone blocker,Cardiovascular drug reviews 21 169 -84
EpsteinM., 2003.Aldosterone receptor blockade and the role of eplerenone: evolving perspectives,Nephrol Dial Transplant 18 1984 -92
PittB,RemmeW,ZannadF,NeatonJ,MartinezF,RonikerB,BittmanR,HurleyS,KleimanJ,GatlinM, 2003.Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction,N Engl J Med 348 1309 -21
ZannadF,McMurrayJJ,KrumH,van VeldhuisenDJ,SwedbergK,ShiH,VincentJ,PocockSJ,PittB., 2011.Eplerenone in patients with systolic heart failure and mild symptoms,N Engl J Med 364 11 -21
NainaK,BrajeshM,ShashankS. Development, 2010.and validation of UV-Spectrophotometric determination of Eplerenone in bulk and tablets,Int J Pharm Life Sci 1 231 -3
UvVoetb, .,Pharmaceutical Sciences. -
BanodeV,KhedekarP,TarteP, 2011.Spectrophotometric estimation of Eplerenone in bulk drug and tablets,Int J Chem Tech Res 3 398 -402
RaneV,PatilK,SangshettiJ,YeoleR,ShindeD, 2009.Stability-indicating RP-HPLC method for analysis of Eplerenone in the bulk drug and in a pharmaceutical dosage form,Acta Pharm 21 619 -29
ZhangJY,FastDM,Breau AP, 2003.A validated SPELC-MS/MS assay for Eplerenone and its hydrolyzed metabolite in human urine,J Pharm Biomed Anal 31 103 -15
GuidelineIH, Switzerland 2005.Validation of analytical procedures: text and methodology Q2 (R1), 11 -2
0

Citations

0

Downloads

72

Views